Peel Hunt reiterated their under review rating on shares of Motif Bio (LON:MTFB) in a research note issued to investors on Monday, ThisIsMoney.Co.Uk reports.
LON:MTFB opened at GBX 2.75 ($0.04) on Monday. The firm has a market cap of $9.42 million and a PE ratio of -0.38. The stock has a fifty day moving average price of GBX 2.54 and a 200 day moving average price of GBX 7.64. Motif Bio has a 12-month low of GBX 2 ($0.03) and a 12-month high of GBX 44.90 ($0.59).
About Motif Bio
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.